Fourth, targeting PD-L1 on cancer cells allows us to block PD-1/PD-L1 interaction, limiting the mechanisms of tumor cell immune evasion, possibly reducing myeloid-derived suppressor cells in the tumor microenvironment [72,73] and favoring T cell activation. Here, PDCD1 is linked to cancer.